An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

Summary

This is a 3-part study. Parts A and B are randomized, double-blind, placebo-controlled, multi-cohort investigations to assess the safety, PK, and PD of single ascending doses (SAD; Part A) and multiple ascending doses (MAD; Part B) of orally-administered A-005. Part C is optional and will be an open-label, one-cohort, single dose study to assess the penetration of orally-administered A-005 into the CSF (Cerebrospinal fluid).

Timeline

Start

2024-04-22

Primary completion

2024-12-18

Completion

2024-12-18

Drugs

Indications

No indication recorded.